Single nucleotide polymorphism array analysis to predict clinical outcome in neuroblastoma patients

Journal of Pediatric Surgery

Volumn 41, Issue 12, 2006, Pages 2032-2036

  Hiyama, Eiso ^a,b   Yamaoka, Hiroaki ^a   Kamimatsuse, Arata ^a   Onitake, Yoshiyuki ^a   Hiyama, Keiko ^b   Nishiyama, Masahiko ^b   Sueda, Taijiro ^a  

^a HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Genetic alteration; Mass screening; Microarray; Neuroblastoma; Prognosis

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DNA EXTRACTION; DNA MICROARRAY; FEMALE; GENE AMPLIFICATION; GENE SEQUENCE; GENETIC SCREENING; GENOMICS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEUROBLASTOMA; NEWBORN; PREDICTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TUMOR REGRESSION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; INFANT, NEWBORN; MASS SCREENING; NERVOUS SYSTEM NEOPLASMS; NEUROBLASTOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33845229331     PISSN: 00223468     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpedsurg.2006.08.002     Document Type: Article

References (25)

1. Young J.L., Ries L.G., Silverberg E., et al. Cancer incidence, survival, and mortality for children under 15 years of age. Cancer 56 (1987) 598-602
2. Schilling F.H., Spix C., Berthold F., et al. Neuroblastoma screening at one year of age. N Engl J Med 346 (2002) 1047-1053
3. Woods W.G., Gao R.N., Shuster J.J., et al. Screening of infants and mortality due to neuroblastoma. N Engl J Med 346 (2002) 1041-1046
4. Yamamoto K., Ohta S., Ito E., et al. Marginal decrease in mortality and marked increase in incidence as a result of neuroblastoma screening at 6 months of age: cohort study in seven prefectures in Japan. J Clin Oncol 20 (2002) 1209-1214
5. Nishihira H., Toyoda Y., Tanaka Y., et al. Natural course of neuroblastoma detected by mass screening: a 5-year prospective study at a single institution. J Clin Oncol 18 (2000) 3012-3017
6. Brodeur G.M. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3 (2003) 203-216
7. Hiyama E., and Hiyama K. Molecular and biological heterogeneity in neuroblastoma. Current Genomics 6 (2005) 319-332
8. Wong K.K., Tsang Y.T., Shen J., et al. Allelic imbalance analysis by high-density single-nucleotide polymorphic allele (SNP) array with whole genome amplified DNA. Nucleic Acids Res 32 (2004) e69
9. Maris J.M., Hii G., Gelfand C.A., et al. Region-specific detection of neuroblastoma loss of heterozygosity at multiple loci simultaneously using a SNP-based tag-array platform. Genome Res 15 (2005) 1168-1176
10. Hayashi Y., Hiyama E., and Tajiri T. Report from committee on tumor registration, Japanese Society of Pediatric Surgeons. J Jap Soc Pediatr Surg 42 (2006) 61-72
11. Kaneko M., Tsuchida Y., Uchino J., et al. Treatment results of advanced neuroblastoma with the first Japanese study group protocol. Study group of Japan for treatment of advanced neuroblastoma. J Pediatr Hematol Oncol 21 (1999) 190-197
12. Yuan E., Haghighi F., White S., et al. A single nucleotide polymorphism chip-based method for combined genetic and epigenetic profiling: validation in decitabine therapy and tumor/normal comparisons. Cancer Res 66 (2006) 3443-3451
13. Kennedy G.C., Matsuzaki H., Dong S., et al. Large-scale genotyping of complex DNA. Nat Biotechnol 21 (2003) 1233-1237
14. Vindelov L.L., Christensen I.J., and Nissen N.I. Detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 3 (1983) 323-327
15. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. Journal of American Statistical Association 53 (1958) 457-481
16. Hiyama E., Hiyama K., Ohtsu K., et al. Biological characteristics of neuroblastoma with partial deletion in the short arm of chromosome 1. Med Pediatr Oncol 36 (2001) 67-74
17. Guo C., White P.S., Weiss M.J., et al. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene 18 (1999) 4948-4957
18. Plantaz D., Vandesompele J., Van Roy N., et al. Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification. Int J Cancer 91 (2001) 680-686
19. Gilbert F., Feder M., Balaban G., et al. Human neuroblastomas and abnormalities of chromosomes 1 and 17. Cancer Res 44 (1984) 5444-5449
20. Breen C.J., O'Meara A., McDermott M., et al. Coordinate deletion of chromosome 3p and 11q in neuroblastoma detected by comparative genomic hybridization. Cancer Genet Cytogenet 120 (2000) 44-49
21. Donti E., Longo L., Tonini G.P., et al. Cytogenetic and molecular study of two human neuroblastoma cell lines. Cancer Genet Cytogenet 30 (1988) 225-231
22. Lastowska M., Cotterill S., Pearson A.D., et al. Gain of chromosome arm 17q predicts unfavourable outcome in neuroblastoma patients. U.K. children's cancer study group and the U.K. Cancer Cytogenetics Group. Eur J Cancer 33 (1997) 1627-1633
23. Attiyeh E.F., London W.B., Mosse Y.P., et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 353 (2005) 2243-2253
24. Hiyama E., Hiyama K., Nishiyama M., et al. Differential gene expression profiles between neuroblastomas with high telomerase activity and low telomerase activity. J Pediatr Surg 38 (2003) 1730-1734
25. Hiyama E., Hiyama K., Yamaoka H., et al. Expression profiling of favorable and unfavorable neuroblastomas. Pediatr Surg Int 20 (2004) 33-38